Antineoplastic 4-piperidone-1-phosphonothioates with potential multi-targeted inhibitory properties
Résumé
Abstract A set of 3,5-bis(ylidene)-4-piperidone-1-phosphonothioates 20a‒l was synthesized in high yields through dehydrochlorination reaction of 3,5-bis(ylidene)-4-piperidones 18a‒l and diethyl chlorothiophosphate 19 in DMF containing quantitative amounts of TEA at 0 °C. Most of the synthesized agents exhibit effective antiproliferation properties against a variety of cancer cell lines (MCF7/breast, HCT116/colon, and A431/skin), outperforming the efficacy of the clinically approved drugs. Compound 20c (R = 3-ClC 6 H 4 ) is the most effective analog discovered with a sub-micromolar activity against MCF7 (IC 50 = 0.650, 3.15 and 3.97 µM, for 20c , 5-fluorouracil, and sunitinib, respectively) as well as remarkable efficacy against HCT116, and A431 (IC 50 = 1.445 and 2.920 µM respectively for 20c , compared to 20.43 and 23.44 µM respectively for 5-fluorouracil). The synthesized analogs demonstrating considerable anti-MCF7 properties were evaluated for their biochemical properties against MDM2, p53, and topoisomerase I/II. Compound 20k [R = 3,4,5-(MeO) 3 C 6 H 2 ] is the most effective anti-MDM2 agent with a potency higher than the standard reference (% inhibition of 65.3, for 20k , and 42.2 for doxorubicin; i.e. 1.55-fold). Biochemical activation of p53 by the synthesized analogs is consistent with the anti-MDM2 properties. Compound 20i (R = 4-MeOC 6 H 4 ) is the most effective topo-I and topo-IIα inhibitor with potency close to that of the standard references (Dxd, and etoposide). Some of the synthesized agents showed selectivity for topo-IIα over topo-I. Molecular docking results (PDB: 4OAS) are consistent with the observed properties against MDM2. Based on the biological and biochemical findings, some of the synthesized compounds could serve as promising multi-targeted inhibitors.
Citer ce document
Accès au document
Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter
Voir l'article sur le site de la revueAuteur(s)
Statistiques
Consultations : 1
Téléchargements : 0